Fosun Pharma Malay acid Avalancopa tablets have been approved clinically.

Fosun Pharmaceuticals was licensed in March 2018 by AkaRx, Inc. (a controlling subsidiary of Dova Pharmaceuticals, IncChinese mainland.;
The new drug is a chemical, mainly applicable to (1) the diagnosis or surgery of chronic liver disease-related plateplate reduction of adult patients, (2) tumor chemotherapy caused by platette reduction, (3) chronic immunoplate plate plate reduction and so on.
As of the date of this announcement, the new drug is applicable to adult patients with chronic liver disease-related plateplate reduction in selected-line diagnostic operations or surgery has been listed in the United States, the European Union, China (excluding Hong Kong, Macao and Taiwan, the same below), and the application of chronic immunoplate plateroid reduction has been listed in the United States.
as of this announcement date, the new drug is suitable for plate plate plate reduction caused by tumor chemotherapy and is in Phase III clinical trials in China.
based on the latest IQVIA MIDASTM data (provided by IQVIA, the world's leading provider of professional information and strategic consulting services for the pharmaceutical and health industry), Avalanco Park Tablets had global sales of approximately $3.43 million in 2019.
as of July 2020, the Group (i.e., the Company and its controlling subsidiaries/units) has invested approximately RMB105.03 million (unaudited; including licensing transfer fees) in research and development for the new drug at this stage.
.